Navigation Links
SGX Initiates Phase I Trials for SGX523
Date:1/16/2008

than 200 protein kinases and has demonstrated both potent in vitro blockage of the activity of this cancer target and in vivo activity against various types of human cancer cells that depend on cMET for their uncontrolled growth and proliferation. The cMET receptor tyrosine kinase has been implicated in a wide range of cancers, including both solid and blood tumors. cMET has been extensively studied in the laboratory environment and, to a lesser extent, in the clinic, with increasing data suggesting that uncontrolled stimulation of cMET plays a key role in a variety of effects associated with cancer, including cellular growth, increased cell movement and invasion, and an increased ability of cancer cells to metastasize. Other observations have implicated cMET in increased angiogenesis. cMET activation has been observed in a wide range of other cancer types including breast, colon, prostate, pancreatic and gastric cancers.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and cMET tyrosine kinase inhibitors, including SGX523, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, the potential of SGX523 as a treatment for certain cancers, the potential outcome of Phase I clinical studies of SGX523, the role of cMET in cancer, statements regarding bringin
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
2. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
3. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
4. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
5. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
6. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
9. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
10. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
11. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Argos Therapeutics, Inc. today announced that its late scientific co-founder ... Nobel Prize in medicine for the discovery of dendritic cells ... Steinman,s discovery of dendritic cells and his research of dendritic ... immunity have led to the development of Argos, core technology, ...
... Ingenious Med welcomes Chief Financial Officer, Mark Adams as ... responsible for the company,s financial, accounting, treasury and ongoing ... executive with high growth companies such as Ingenious Med," ... financial background and experience will bring tremendous value to ...
Cached Medicine Technology:Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System 2New Chief Financial Officer, Mark Adams, Joins Ingenious Med 2
(Date:7/31/2015)... ... July 31, 2015 , ... ... Group, Inc. has re-branded their social media profiles to better connect with the ... consumers to communicate, find information, share insights and opinions. The Rally Insurance Group, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... Those looking to catch a new and refreshing show on Broadway, look no further ... achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel ...
(Date:7/31/2015)... ... 31, 2015 , ... Well-known for its unique pastries and delicious confections, Pastry ... custom designs, making life just a little bit sweeter for newlyweds. A family-owned business, ... who orders one. , The bakery provides a full line of custom wedding cakes. ...
(Date:7/31/2015)... ... 2015 , ... As part of their company mission, Dallas pet sitting ... organizations is essential to the longevity of their business. It is for that ... Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply drive. Presents 4 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Creating one of the most modern fertility ... a visionary image that goes beyond the boundaries of fertility medicine. , As ... extraordinary heights with dependable patient support, affordable treatments, unending hope, and high fertility success ...
Breaking Medicine News(10 mins):Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... -- About one million packets of birth control pills are ... of a packaging error that could reduce the effectiveness of ... 14 lots of Lo/Ovral-28 tablets and 14 lots of generic ... Pfizer discovered that some blister packs may contain either too ...
... , WEDNESDAY, Feb. 1 (HealthDay News) -- Scientists may one ... lost the ability to speak, new research suggests. In their ... journal PLoS Biology , University of California, Berkeley researchers describe ... waves in order to reconstruct words the person hears in normal ...
... Heart Month, on Wednesday, Feb. 8, 2012, the National Heart, ... the support of the Foundation for the National Institutes of ... Collection 2012 at Mercedes-Benz Fashion Week in New York City. ... Heart Truth has partnered with Million Hearts, a national initiative ...
... Most studies that have examined growing levels of health ... between the "haves" and the "have-nots" in terms of socioeconomic ... study has found, for the first time, that health disparities ... often times more than the disparities have grown between ...
... Reinberg HealthDay Reporter , TUESDAY, Jan. 31 ... 180 prostate genes among men with early stage prostate ... genes known to suppress tumor growth and repair DNA, ... progression of the disease, the researchers said. "There ...
... and 2009, the musculoskeletal (MSK) ultrasound volume increase among ... to a study in the February issue of the ... Ultrasound images of the MSK system provide pictures of ... body. Over the past two decades, MSK ...
Cached Medicine News:Health News:Pfizer Recalls 1 Million Packets of Birth Control Pills 2Health News:Scientists Use Brain Waves to Eavesdrop on the Mind 2Health News:The NIH urges women to protect their heart health 2Health News:The NIH urges women to protect their heart health 3Health News:The NIH urges women to protect their heart health 4Health News:Study reveals new wrinkle in growing US health gap 2Health News:Study reveals new wrinkle in growing US health gap 3Health News:Science Shows How Exercise Might Help in Prostate Cancer 2Health News:Science Shows How Exercise Might Help in Prostate Cancer 3
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Digitoxin in human serum....
For the quantitative in vitro determination of Phenytoin in human serum....
Medicine Products: